De Novo Classification Requests: Navigating FDA Approval When Your Device Has No Predicate

Your Device Is Innovative. That Is Exactly the Problem.

You have built something genuinely new. Your device does not fit neatly into an existing FDA product code, and there is no legally marketed predicate you can point to for a 510(k) submission. Congratulations — and also, welcome to one of the most misunderstood regulatory pathways in the FDA toolkit: the De Novo classification request.

For medical device startups and small-to-mid-size companies developing novel, low-to-moderate risk technologies, the De Novo pathway is not a consolation prize. When used strategically, it is a powerful route to market that simultaneously establishes your device as a predicate for future 510(k) submitters. But it requires a fundamentally different mindset than a standard 510(k), and underestimating its complexity is a mistake that costs companies months and significant capital.

What De Novo Actually Is — and Is Not

Established under Section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act and further codified through the 21st Century Cures Act, the De Novo process allows FDA to create a new device classification for novel devices that are low to moderate risk but lack a predicate. It is not a PMA lite. It is not a shortcut. It is a classification mechanism that, if granted, places your device into Class I or Class II with special controls that FDA defines — often with your direct input.

Per 21 CFR Part 860, Subpart D, a De Novo request can be submitted in one of two ways: following a Not Substantially Equivalent (NSE) determination after a 510(k) submission, or directly without first submitting a 510(k). Since 2017, the direct De Novo pathway has become increasingly common and is generally preferred for devices where predicate absence is obvious from the outset.

When De Novo Is the Right Call

The decision to pursue De Novo should be deliberate, not default. Ask these questions before committing to the pathway:

• Is your device Class III by default? Under 21 CFR 860.3, any device that cannot be classified into Class I or II through 510(k) is automatically Class III — requiring PMA. De Novo is the mechanism to reclassify it downward if the risk profile supports it.
• Can general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness? This is the statutory standard. If your device genuinely requires clinical evidence typical of a PMA, De Novo may not be appropriate.
• Does your device fall into an existing product code with a different intended use? Sometimes what appears to be a De Novo situation is actually a 510(k) with a well-scoped intended use statement. This distinction matters enormously.
• Are you prepared to help FDA draft special controls? This is one of the most underappreciated aspects of De Novo. The special controls that emerge from your request will govern not just your device, but every future 510(k) predicated on it.

Building a De Novo Request That Does Not Get Rejected

FDA's acceptance rate for De Novo requests has improved, but substantive deficiencies remain common. The most frequent issues we see at ADB Consulting and CRO Inc. involve three areas: risk classification justification, special controls development, and the performance testing package.

Risk Classification Justification

Your De Novo request must convincingly argue that your device belongs in Class I or Class II. This means a thorough benefit-risk analysis grounded in FDA's guidance document 'De Novo Classification Process (Evaluation of Automatic Class III Designation),' finalized in 2021. Reference the factors outlined in 21 CFR 860.7 and align your narrative to FDA's own framework. Generalities will not hold up to review.

Proposed Special Controls

This section separates experienced regulatory teams from inexperienced ones. You are essentially proposing the regulatory controls that will define your device type going forward. Special controls typically include design requirements, performance testing standards, biocompatibility per ISO 10993, labeling requirements, and post-market surveillance obligations. Draft them specifically enough to be enforceable, but not so narrowly that they prevent you from iterating your own product.

Performance Testing Package

Bench testing, biocompatibility, software documentation (per IEC 62304 if applicable), electrical safety, and — where indicated — clinical data must be scoped to your device's risk profile. FDA's review clock under MDUFA IV targets 150 days for De Novo requests, but a deficient package will restart that clock.

Q-Submission First. Always.

Before submitting a De Novo request, engage FDA through the Q-Submission (Pre-Sub) program. This is not optional for complex devices. A well-constructed Pre-Sub meeting allows you to align on the classification rationale, confirm the testing FDA expects, and surface objections before they become a Refuse to Accept or a deficiency letter. Skipping this step is one of the most expensive shortcuts a company can take.

The Strategic Value Most Companies Miss

A granted De Novo does more than clear your device for market. It creates a new product code and establishes your device as a Class II predicate. If your commercial strategy includes platform expansion, this has long-term competitive and portfolio implications worth planning for from day one — not after clearance.

Ready to Determine the Right Pathway for Your Device?

At ADB Consulting and CRO Inc., Andre Butler and the team work directly with startup founders, VP-level regulatory affairs leaders, and quality executives to assess pathway feasibility, structure submissions, and guide devices through FDA review with precision. Whether you are at ideation or staring down an NSE determination, we can help you move forward with clarity.

Book your free discovery call today at adbccro.com and get a candid, expert assessment of your regulatory situation — no fluff, no generic advice, just a clear path forward.